JRCT ID: jRCT2080223749
Registered date:11/12/2017
Basic Information
Recruitment status | completed |
---|---|
Health condition(s) or Problem(s) studied | |
Date of first enrollment | 15/12/2017 |
Target sample size | 160 |
Countries of recruitment | Japan,Asia except Japan,North America,South America,Europe,Oceania |
Study type | Interventional |
Intervention(s) | investigational material(s) Generic name etc : INN of investigational material : alperisib Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : control material(s) Generic name etc : INN of investigational material : - Therapeutic category code : Dosage and Administration for Investigational material : |
Outcome(s)
Primary Outcome | efficacy |
---|---|
Secondary Outcome | safety efficacy |
Key inclusion & exclusion criteria
Age minimum | >= 18age old |
---|---|
Age maximum | Not applicable |
Gender | Both |
Include criteria | |
Exclude criteria |
Related Information
Primary Sponsor | Novartis Pharma K.K. |
---|---|
Secondary Sponsor | - |
Source(s) of Monetary Support | - |
Secondary ID(s) | NCT03056755,JapicCTI-173805 |
Contact
Public contact | |
Name | |
Address | - |
Telephone | +81-120-003-293 |
Affiliation | Novartis Pharma K.K. |
Scientific contact | |
Name | |
Address | - |
Telephone | +81-120-003-293 |
Affiliation | Novartis Pharma K.K. |